Compare NTRA & NTNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTRA | NTNX |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.0B | 14.1B |
| IPO Year | 2015 | 2016 |
| Metric | NTRA | NTNX |
|---|---|---|
| Price | $235.54 | $52.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 16 |
| Target Price | ★ $238.20 | $76.20 |
| AVG Volume (30 Days) | 1.2M | ★ 6.1M |
| Earning Date | 11-06-2025 | 11-25-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.76 |
| Revenue | $2,116,676,000.00 | ★ $2,617,547,000.00 |
| Revenue This Year | $33.18 | $14.23 |
| Revenue Next Year | $16.81 | $14.00 |
| P/E Ratio | ★ N/A | $68.56 |
| Revenue Growth | ★ 38.17 | 17.45 |
| 52 Week Low | $125.38 | $46.12 |
| 52 Week High | $246.90 | $83.36 |
| Indicator | NTRA | NTNX |
|---|---|---|
| Relative Strength Index (RSI) | 62.16 | 44.92 |
| Support Level | $221.84 | $51.51 |
| Resistance Level | $237.04 | $53.34 |
| Average True Range (ATR) | 6.22 | 1.42 |
| MACD | -1.38 | 1.29 |
| Stochastic Oscillator | 54.67 | 79.16 |
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Nutanix Inc is engaged in cloud software, offering organizations a single platform for running applications and managing data anywhere. Its Nutanix Cloud Platform is designed to enable organizations to build a hybrid multicloud infrastructure, providing a consistent cloud operating model with a single platform for running applications and managing data in core data centers, at the edge, and in public clouds, all while supporting a variety of hypervisors and container platforms. The company operates a single operating and reportable segment based on a subscription business model. It conducts business in the United States, Europe, the Middle East and Africa, Asia Pacific, and other Americas, with key revenue generated from the United States.